Newly public Candel looks to two years of value inflection points

Less than a year after announcing a new leadership team, Candel believes it has the funding it needs to get to a pivotal readout for its lead viral immunotherapy, as well as advance its early stage programs and build a manufacturing facility.

“There are going to be a range of value-creating inflection points in the next two years,” said CEO Paul Peter Tak. ...